

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (currently amended) A biologically active polypeptide having the amino acid sequence consisting essentially of AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄ (SEQ ID NO:1), wherein:

X₀₁ is Ala, Asp or Gln;

X₀₂ is Leu, Arg or homoArg;

X₀₃ is Arg or Ala; and

X₀₄ is Phe or Trp.

2. (currently amended) A biologically active polypeptide having an amino acid sequence that is at least 90% identical to the amino acid sequence of the polypeptide of claim 1.

3. (withdrawn) A polypeptide comprising an amino acid sequence consisting essentially of AlaValAlaGluIleGlnLeuMetHisX₀₁ArgAlaLysX₀₂ (SEQ ID NO:2), wherein :

X₀₁ is Ala, Asp or Gln; and

X₀₂ is Trp or His.

4. (withdrawn) A polypeptide having an amino acid sequence that is at least 85% identical to the amino acid sequence of the polypeptide of claim 3.

5. (withdrawn) A polypeptide comprising the amino acid sequence:
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅Arg (SEQ ID NO:25),
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅ArgValGlu (SEQ ID NO:26),
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅ArgValGluTrpLeu (SEQ ID
NO:27), AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅
ArgValGluTrpLeuArgLys (SEQ ID NO:28),
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅ArgVal
GluTrpLeuArgLysLysLeu (SEQ ID NO:29),
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅ArgValGluTrpLeuArgLys
LysLeuGlnAsp (SEQ ID NO:30), or
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetX₀₅ArgValGluTrpLeuArgLys
LysLeuGlnAspValHis (SEQ ID NO:31) wherein:

X₀₁ is Ala, Asp or Gln;

X₀₂ is Leu, Arg or homoArg;

X₀₃ is Arg or Ala;

X₀₄ is Phe or Trp; and

X₀₅ is Arg or Ala.

6. (withdrawn) A polypeptide having an amino acid sequence that is at least 90% identical
to the amino acid sequence of the polypeptide of claim 5.

7. (withdrawn) A polypeptide having an amino acid sequence selected from the group of
sequences consisting of: AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysHis

(SEQ ID No:3), AlaValSerGluIleGlnLeuMetHisAsnArgGlyLysHis (SEQ ID No:4),
AlaValSerGluIleGlnLeuMetHisAsnArgAlaLysHis (SEQ ID No:5),
AlaValAlaGluIleGlnLeuMetHisAsnArgAlaLysHis (SEQ ID No:6),
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysTrp (SEQ ID No:7),
AlaValAlaGluIleGlnLeuMetHisGlnArgAlaLysHis (SEQ ID No:8),
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLys (SEQ ID No:9),
AlaValAlaGluIleGlnLeuMetHisAlaArgAla (SEQ ID No:10),
AlaValAlaGluIleGlnLeuMetHisAlaArg (SEQ ID No:11),
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysHisLeuAsnSerMetGluArgValGluTrpLeuArgL
ysLysLeuGlnAspValHisAspTyr (SEQ ID No:12) and
AlaValSerGluIleGlnLeuMetHisAlaArgAlaLysHis (SEQ ID No:13),
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysHisLeuAlaSerValGluArgMetGlnTrpLeuArgL
sLysLeuGlnAspValHisAspTyr (SEQ ID No:20),
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysHisLeuAsnSerMetGluArgValGluTrpLeuArgL
ysLysLeuGlnAspValHisAspTyr (SEQ ID No:22),
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysHisLeuAlaSerValArgArgMetGlnTrpLeuArgL
ysLysLeuGlnAspValHisAspTyr (SEQ ID No:23)
AlaValAlaGluIleGlnLeuMetHisAlaArgAlaLysHisLeuAsnSerMetArgArgValGluTrpLeuArgL
ysLysLeuGlnAspValHisAspTyr (SEQ ID No:24)

8. (currently amended) The biologically active polypeptide of ~~any of claims 1-7~~ claim 1,
wherein said polypeptide contains a C-terminal amide.

9. (cancelled).

10. (currently amended) The biologically active polypeptide of claim 1 wherein said peptide is labeled with a label selected from the group consisting of: a radiolabel, a fluorescent label, a bioluminescent label, or a chemiluminescent label.

11. (currently amended) The biologically active polypeptide of claim 10, wherein said radiolabel is ^{99m}Tc.

12. (currently amended) A pharmaceutical composition comprising:

- (a) the biologically active polypeptide of claim 1; and
- (b) a pharmaceutically acceptable carrier.

13. (withdrawn) An isolated nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of claim 1.

14. (withdrawn) An isolated nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of claim 7.

15. (withdrawn) A recombinant DNA molecule comprising: (1) an expression control region, said region operably linked to (2) a polynucleotide sequence coding for the polypeptide of claim 1.

16. (withdrawn) A method of preparing a polypeptide, comprising introducing the nucleic acid of claim 13 into a host and expressing the polypeptide encoded by said nucleic acid.

17. (withdrawn) A method for making a recombinant vector comprising inserting a nucleic acid molecule of claim 13 into a vector.

18. (withdrawn) The recombinant DNA molecule of claim 15, wherein said control region includes a bacterial, viral, fungal or mammalian promoter.

19. (withdrawn) A prokaryotic or eukaryotic host cell containing the recombinant DNA molecule of claim 15.

20. (withdrawn) The cell of claim 19 which is bacterial.

21. (withdrawn) The cell of claim 19 which is a yeast cell or a mammalian cell.

22. (withdrawn) A polypeptide having the amino acid sequence of SEQ ID NO:14, wherein a single amino acid substitution reduces cAMP stimulation relative to the native PTH in HKRK-B7 cells, provided that said substitution is not alanine at any position, the substitution at Ser-1 is not Tyr, Pro or Asp, the substitution at Val-2 is not Leu, Ser, Arg or Glu, the substitution at Ser-3 is not Thr, Gly, Ile, or Asn and the substitution at Glu-4 is not Gly, His, Lys, Val or Asp.

23. (withdrawn) A polypeptide having the amino acid sequence of SEQ ID NO:14, wherein a single amino acid substitution increases cAMP stimulation in HKRK-B7 cells relative to the native PTH polypeptide, provided that said substitution is not alanine.

24. (withdrawn) The polypeptide of claim 21 wherein said single amino acid substitution is selected from the group consisting of:

- (a) Asn-10 --> Asp, Glu or Gln;
- (b) Leu-11 --> Ile, Met, Lys, Arg or Trp;
- (c) Gly-12 --> Arg or His;
- (d) Lys-13 --> Leu, Arg, His or Trp; and
- (e) His-14 --> Leu, Arg, Phe or Trp.

25. (withdrawn) The polypeptide of claim 21, wherein said polypeptide contains amino acids 1-9, 1-10, 1-11, 1-12 or 1-13.

26. (withdrawn) A polypeptide selected from the group consisting of: PTH (1-20), PTH (1-22), PTH (1-24), PTH (1-26), PTH (1-28), PTH (1-30), PTH (1-32) and PTH(1-34), wherein a single amino acid substitution increases cAMP stimulation in HKRK-B7 cells relative to the native PTH polypeptide, provided that said substitution is not alanine.

27. (withdrawn) The polypeptide of claim 25 wherein said single amino acid substitution is selected from the group consisting of:

- (a) Asn-10 --> Asp, Glu or Gln;

- (b) Leu-11 --> Ile, Met, Lys, Arg or Trp;
- (c) Gly-12 --> Arg or His;
- (d) Lys-13 --> Leu, Arg, His or Trp; and
- (e) His-14 --> Leu, Arg, Phe or Trp.
- (f) Glu-19 --> Arg

28. (withdrawn) The polypeptide of claim 21, wherein said polypeptide contains amino acids 1-9, 1-10, 1-11, 1-12, 1-13, 1-14, 1-20, 1-22, 1-24, 1-26, 1-28, 1-30, or 1-32.

29. (withdrawn) A method for treating mammalian conditions characterized by decreases in bone mass, wherein said method comprises administering to a subject in need thereof an effective bone mass-increasing amount of the polypeptide of any one of claims 1.

30. (withdrawn) A method for determining rates of bone reformation, bone resorption and/or bone remodeling comprising administering to a patient an effective amount of a polypeptide of any one of claims 1 and determining the uptake of said peptide into the bone of said patient.

31. (withdrawn) The method of claim 29, wherein said effective bone mass-increasing amount of said peptide is administered by providing to the patient DNA encoding said peptide and expressing said peptide *in vivo*.

32. (withdrawn) The method of claim 29, wherein the condition to be treated is

osteoporosis.

33. (withdrawn) The method of claim 32, wherein said osteoporosis is old age osteoporosis.

34. (withdrawn) The method of claim 32, wherein said osteoporosis is post-menopausal osteoporosis.

35. (withdrawn) The method of claim 29, wherein the effective amount of said polypeptide for increasing bone mass is from about 0.01 $\mu\text{g/kg/day}$ to about 1.0 $\mu\text{g/kg/day}$.

36. (withdrawn) The method of claim 29, wherein the method of administration is parenteral.

37. (withdrawn) The method of claim 29, wherein the method of administration is subcutaneous.

38. (withdrawn) The method of claim 29, wherein the method of administration is nasal insufflation.

39. (withdrawn) A method of increasing cAMP in a mammalian cell having PTH-1 receptors, comprising contacting said cell with a sufficient amount of the polypeptide of claim 1 to increase cAMP in said cell.

40. (withdrawn) A polypeptide having the amino acid sequence
AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAsnSerMetGluArgValGluTrpLeuArgLy
s L y s L e u G l n A s p V a l H i s A s p X₀₅ (SEQ ID NO:16) o r
SerValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄LeuAlaSerValGluMetGlnGlu
TrpLeuArgLysLysLeuGlnAspValHisAspX₀₅ (SEQ ID NO:21), wherein
X₀₁ is Ala Asp; X₀₂ is Leu or Arg; X₀₃ is Arg or Ala; X₀₄ is Phe or Trp; and X₀₅ is Phe or Tyr.

41. (withdrawn) A method of increasing inositol phosphate in a mammalian cell having
PTH-1 receptors, comprising contacting said cell with a sufficient amount of the polypeptide of
claim 1 to increase inositol phosphate in said cell.

42. (new) A biologically active polypeptide having an amino acid sequence, said sequence
consisting essentially of a sequence selected from the group consisting of:

- (a) AlaValAlaGluIleGlnLeuMetHisX₀₁X₀₂X₀₃LysX₀₄ (SEQ ID NO:1);
- (b) N- or C- derivatives thereof; and
- (c) fragments containing amino acids 1-9, 1-10, 1-11, 1-12 or 1-13 thereof;

wherein: X₀₁ is Ala, Asp or Gln;
X₀₂ is Leu, Arg or homoArg;
X₀₃ is Arg or Ala; and
X₀₄ is Phe or Trp.